Drug Profile
Research programme: antibody-drug congugate therapeutics - CytomX Therapeutics
Alternative Names: Integrin alpha 3 Probody™-drug conjugate - CytomX Therapeutics; ITGA3 PDC - CytomX TherapeuticsLatest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator CytomX Therapeutics
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Integrin alpha chain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer